Forbes July 16, 2024
Predicta Biosciences is using precision medicine to diagnose and monitor multiple myeloma–and give doctors insights for better treatment plans.
Over 35,000 Americans are diagnosed with a blood cancer called multiple myeloma every year. But figuring out a patient has it isn’t easy — doctors still rely on invasive and painful decades-old tests like bone marrow biopsies to make the determination.
Precision oncology company Predicta Biosciences hopes to change that by offering patients non-invasive, diagnostic tests from a simple blood draw. The company says its tech can accurately diagnose and monitor multiple myeloma to help guide physicians’ treatment plans.
Today, Predicta announced a new, oversubscribed $5.2 million round of seed funding, led by The Engine Ventures with additional funding from Illumina...
Today's Sponsors
Today's Sponsor